Developing Innovative Cancer Immunotherapies

Learn about our pipeline

Clinical Trials
Recruiting

Developing innovative internally discovered small molecule drug candidates as well as antibody candidates that target immuno-oncology pathways

learn more

We’re Hiring!
Growth

Arcus Biosciences is an exciting young company founded on the vision of creating new cancer therapeutics through the translation of unexploited insights in immunology.

learn more

Press Releases
Recent News

view all

MEDIA

Adenosine dreams fueling new approaches in cancer; Arcus embarks on phase I

By Randy Osborne, Staff Writer

Although Merck & Co. Inc. continues to chalk up investor-pleasing sales with Keytruda (pembrolizumab) and Bristol-Myers Squibb Co. (BMS) keeps doing well with Opdivo (nivolumab), researchers have yet to strike upon the best combinations with other agents.

Keep Reading

PIPELINE

 
Discovery
Preclinical
Phase 1
Phase 1b Dose Esc.

AB928 (A2aR/A2bR Antagonist) ⇓

AB928 + AB122 (anti-PD-1)
 
 
 
AB928 + Chemotherapy
 
 
 

AB680 (Small Molecule CD73i) ⇓

AB680 (IV)
 
 
Phase 1 in HVs initiated
AB680 (oral)
 
 
IND-enabling

Antibody Programs ⇓

AB122 (anti-PD-1 Antibody)
 
 
Enrolling in solid tumors
AB154 (anti-TIGIT Antibody)
 
 
Enrolling in solid tumors

Other Small Molecules ⇓

AB745 (A2aR Antagonist)
 
 
IND-enabling
Arginase inhibitor
 
 
Lead optimization
Learn more

Arcus has significant expertise in immunology, medicinal chemistry, biochemistry, enzymology, pharmacology, and structural biology.

Meet Our Leadership